The Fine Print of R&D: How Biotech Firms Can Optimize Tax Savings Amid Regulatory Changes
Discover how biotech firms can maximize R&D tax savings amid evolving regulations, focusing on key tax considerations and strategies for compliance.
In this inaugural episode, we dive deep into the essential elements of building a resilient business equipped to thrive in an unpredictable landscape. Join us as we welcome Risk Advisory experts, Jizzalyn Cruz and Matthew Gopez, to share their insights on cultivating a strong culture of control. Discover how to foster a proactive mindset, empower your team, and harness data-driven strategies to mitigate risks and capitalize on opportunities. Tune in for practical advice on safeguarding your business’s long-term success.
Jizzalyn is a Risk Advisory Group Manager with 9 years of experience in SOX compliance audit and integrated audits. Her expertise lies in leading teams, conducting thorough business process reviews, and ensuring adherence to stringent internal controls. With a strong foundation in accounting principles and a proven track record at Scrubbed and SGV & Co. (EY Philippines).
Matthew is a Risk Advisory Senior Manager with over 8 years of experience in financial audits, internal controls, and compliance. He is a CPA, CIA, CISA, and US CPA with expertise in various industries (Life Sciences, Technology, Retail, Manufacturing). His focus areas include Sarbanes-Oxley compliance, internal controls, and business process improvement. He has led multiple engagements under US GAAP, UK GAAP, and IFRS.
Share on:
Discover how biotech firms can maximize R&D tax savings amid evolving regulations, focusing on key tax considerations and strategies for compliance.
Over 300,000 accountants have left the profession, leaving CPA firms facing a talent crisis. Discover strategies to attract and retain top accounting talent in our new report.